Adipose Stem Cells attenuates Bleomycin induced Pulmonary Fibrosis

• Published in: The FASEB journal 2015-04, Vol.29 (S1)
• Main Authors: Rathinasabapathy, Anandharajan, Shenoy, Vinayak, Horowitz, Alana, Guzzo, Dominic, Jaekel, Sina, Raizada, Mohan, Katovich, Michael
• Format: Article
• Language: English
• ISSN: 0892-6638; 1530-6860
• DOI: 10.1096/fasebj.29.1_supplement.lb750

Abstract only Pulmonary Fibrosis (PF), a progressive lung disease, resulting in extensive tissue modeling ultimately leads to mortality. Existing therapy does not curtail the rate of mortality. Here, the protective role of adipose stem cell (ASC) in PF was studied. Bleomycin (Bleo) was injected into 8‐weeks old male SD rats to induce PF. Post 3 days of Bleo challenge, 1X10 6 ASC were administered through the jugular vein. After 2 weeks of Bleo injection, Picro Sirius and H&E staining demonstrated a significant lung tissue remodeling and fibrosis. Further, ventricular hemodynamics of Bleo‐treated animals was significantly dysregulated, RVSP (28.88±1.39 vs 45.02±3.62 mmHg) and right ventricular hypertrophy (RVH; 0.26±0.02 vs 0.39±0.04). Echocardiography (ECHO) results demonstrated that the ratio of RV/LV (End‐Diastolic Area; 0.31±0.02 vs 0.63±0.03 %) and (Ejection Fraction; 1.39±0.03 vs 1.90±0.06 %) was significantly dysregulated in PF. ASC therapy significantly attenuated the tissue remodeling and fibrosis with a concomitant reduction in RVSP (33.29±2.32) and RVH (0.32±0.03). In addition, ASC therapy normalized all the ECHO parameters. In a separate study, ASC was administered after 7 days of bleo injections. Similar to day 3, day 7 therapy also prevented the progression of PF. Collectively, our data demonstrate that ASC based cell‐therapy arrested PF and associated cardiac remodeling, suggesting, ASC intervention could be a potential therapeutic strategy for the treatment of PF.